Michel P, Lemaire M, Colin R, Bommelaer G, Rambaud J C, Dupas J L, Bigard M A, Verwaerd J C
Hôpital Charles Nicolle, Rouen, France.
Aliment Pharmacol Ther. 1994 Feb;8(1):119-22. doi: 10.1111/j.1365-2036.1994.tb00167.x.
We studied the effectiveness of lansoprazole and ranitidine in promoting gastric ulcer healing in a multicentre double-blind trial, by comparing the proportion of healed ulcers after 4 and 8 weeks of treatment. One hundred and fifty-eight patients were randomly given either ranitidine (150 mg each morning and at bedtime) or lansoprazole (30 mg each morning and placebo at bedtime). One hundred and twenty-eight patients completed the trial (62 taking lansoprazole, 66 taking ranitidine). Fifty-one (80%) of those treated with lansoprazole and forty-two (62%) of those treated with ranitidine had healed ulcers at 4 weeks (P < 0.05). Sixty-one (98%) patients who received lansoprazole and 57 (86%) who received ranitidine had healed ulcers at 8 weeks (P < 0.05). The observed differences were not significant in the intention-to-treat analysis. No serious adverse event was reported with lansoprazole.
我们在一项多中心双盲试验中,通过比较治疗4周和8周后溃疡愈合的比例,研究了兰索拉唑和雷尼替丁促进胃溃疡愈合的有效性。158名患者被随机给予雷尼替丁(每天早晨和睡前各150毫克)或兰索拉唑(每天早晨30毫克,睡前服用安慰剂)。128名患者完成了试验(62名服用兰索拉唑,66名服用雷尼替丁)。接受兰索拉唑治疗的患者中有51名(80%)在4周时溃疡愈合,接受雷尼替丁治疗的患者中有42名(62%)在4周时溃疡愈合(P<0.05)。接受兰索拉唑治疗的61名(98%)患者和接受雷尼替丁治疗的57名(86%)患者在8周时溃疡愈合(P<0.05)。在意向性分析中,观察到的差异不显著。使用兰索拉唑未报告严重不良事件。